A carregar...
Tocilizumab and COVID-19: Timing of administration assessment
Recent evidence showed greater efficacy of tocilizumab (TCZ) in the subgroups of COVID-19 patients who presented with symptoms for less than 7 days and in those only receiving oxygen. We retrospectively analyzed a compassionate use cohort to determine the best timing for TCZ injection. We showed no...
Na minha lista:
| Publicado no: | Infect Dis Now |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Elsevier Masson SAS.
2022
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8239201/ https://ncbi.nlm.nih.gov/pubmed/34198000 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.idnow.2021.06.304 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|